Non-small cell lung cancer (NSCLC) patients with brain metastases who have activating mutations of epidermal growth factor receptor (EGFR) tend to do significantly better as compared to those with wild type EGFR (median survival of 12.9 months as compared to 3.1 months) [4], when treated with oral tyrosine kinase inhibitors (TKIs) and cranial irradiation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.